Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MET Stock Forecast 2026-2027
$78.08
Current Price
$50.38B
Market Cap
Buy 12
Hold 6
Sell 0
Wall St Analyst Ratings
Distance to MET Price Targets
+35.8%
To High Target of $106.00
+14.6%
To Median Target of $89.50
-3.9%
To Low Target of $75.00
MET Price Momentum
-2.7%
1 Week Change
+4.6%
1 Month Change
+0.3%
1 Year Change
-1.1%
Year-to-Date Change
-6.9%
From 52W High of $83.85
+16.0%
From 52W Low of $67.33
📊 TOP ANALYST CALLS
Did MET Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if MetLife is one of their latest high-conviction picks.
Latest MET Stock Price Targets & Analyst Predictions
Based on our analysis of 26 Wall Street analysts, MET has a bullish consensus with a median price target of $89.50 (ranging from $75.00 to $106.00). The overall analyst rating is Strong Buy (8.2/10). Currently trading at $78.08, the median forecast implies a 14.6% upside. This outlook is supported by 12 Buy, 6 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Elyse Greenspan at Wells Fargo, suggesting a 3.9% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MET Analyst Ratings
12
Buy
6
Hold
0
Sell
MET Price Target Range
Low
$75.00
Average
$89.50
High
$106.00
Current: $78.08
Latest MET Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MET.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 7, 2026 | Barclays | Alex Scott | Overweight | Maintains | $93.00 |
| Apr 14, 2026 | B of A Securities | Joshua Shanker | Buy | Maintains | $99.00 |
| Apr 13, 2026 | Mizuho | Yaron Kinar | Outperform | Maintains | $93.00 |
| Apr 10, 2026 | Wells Fargo | Wesley Carmichael | Overweight | Maintains | $90.00 |
| Apr 9, 2026 | Evercore ISI Group | Thomas Gallagher | In-Line | Maintains | $96.00 |
| Apr 9, 2026 | UBS | Michael Ward | Buy | Maintains | $102.00 |
| Apr 8, 2026 | Barclays | Alex Scott | Overweight | Maintains | $89.00 |
| Mar 26, 2026 | Keefe, Bruyette & Woods | Ryan Krueger | Outperform | Reinstates | $87.00 |
| Mar 11, 2026 | TD Cowen | Andrew Kligerman | Buy | Maintains | $88.00 |
| Mar 3, 2026 | Morgan Stanley | Nigel Dally | Overweight | Maintains | $93.00 |
| Feb 25, 2026 | Wells Fargo | Wesley Carmichael | Overweight | Maintains | $93.00 |
| Feb 11, 2026 | Evercore ISI Group | Thomas Gallagher | In-Line | Maintains | $95.00 |
| Feb 5, 2026 | UBS | Brian Meredith | Buy | Maintains | $98.00 |
| Jan 13, 2026 | Wells Fargo | Elyse Greenspan | Overweight | Maintains | $97.00 |
| Jan 8, 2026 | UBS | Brian Meredith | Buy | Maintains | $94.00 |
| Dec 23, 2025 | Wells Fargo | Elyse Greenspan | Overweight | Maintains | $94.00 |
| Dec 16, 2025 | Mizuho | Yaron Kinar | Outperform | Initiates | $101.00 |
| Nov 11, 2025 | Keefe, Bruyette & Woods | Ryan Krueger | Outperform | Maintains | $90.00 |
| Nov 7, 2025 | Wells Fargo | Elyse Greenspan | Overweight | Maintains | $92.00 |
| Nov 6, 2025 | B of A Securities | Buy | Maintains | $N/A |
MetLife Inc. (MET) Competitors
The following stocks are similar to MetLife based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
MetLife Inc. (MET) Financial Data
MetLife Inc. has a market capitalization of $50.38B with a P/E ratio of 15.2x. The company generates $77.58B in trailing twelve-month revenue with a 4.7% profit margin.
Revenue growth is +2.7% quarter-over-quarter, while maintaining an operating margin of +9.9% and return on equity of +13.0%.
Valuation Metrics
Market Cap
$50.38B
Enterprise Value
$63.82B
P/E Ratio
15.2x
PEG Ratio
-0.5x
Price/Sales
0.7x
Growth & Margins
Revenue Growth (YoY)
+2.7%
Gross Margin
N/A
Operating Margin
+9.9%
Net Margin
+4.7%
EPS Growth
+25.4%
Financial Health
Cash/Price Ratio
+54.3%
Current Ratio
4.4x
Debt/Equity
142.4x
ROE
+13.0%
ROA
+0.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
MetLife Inc. (MET) Business Model
About MetLife Inc.
What They Do
Global provider of insurance and financial services.
Business Model
MetLife Inc. generates revenue through a diverse range of insurance products, including life and health insurance, as well as annuities and employee benefit programs. The company serves both individual and institutional clients, offering tailored solutions that address personal and organizational financial needs. Its broad geographic reach allows it to tap into various markets, enhancing its revenue streams.
Additional Information
Founded in 1868 and headquartered in New York City, MetLife operates in multiple regions, including the U.S., Asia, and Europe. The company is committed to innovation in its product offerings, ensuring that it meets the evolving demands of its clients while providing financial security and protection.
Company Information
Sector
Financial Services
Industry
Insurance - Life
Employees
46,000
CEO
Mr. Michel Abbas Khalaf
Country
United States
IPO Year
2000
Website
www.metlife.comMetLife Inc. (MET) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
MET Tops Q1 EPS Estimates on Strong Investment Income and Volume Growth
MetLife posts a Q1 earnings beat as investment income, underwriting gains and strong segment growth lift profits and revenues.
May 07, 2026
By Zacks Equity Research
Analyst Blog
MetLife (MET) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for MetLife (MET) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
May 06, 2026
By Zacks Equity Research
Fundamental Analysis
Enact Holdings, Inc. (ACT) Misses Q1 Earnings Estimates
Enact Holdings (ACT) delivered earnings and revenue surprises of -3.59% and +1.80%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
May 05, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
MetLife, Inc. (NYSE: MET) released a financial update video for Q1 2026 by CFO John McCallion, available on their website. MetLife is a leading global financial services provider.
Why It Matters
MetLife's CFO's financial update signals transparency and may influence investor confidence, impacting stock performance and market perception of the company’s future.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
MetLife's Q1 2026 revenue and EPS performance should be evaluated against Wall Street estimates and year-ago figures for a comprehensive analysis.
Why It Matters
MetLife's revenue and EPS performance relative to Wall Street estimates and previous year figures indicates growth potential or weaknesses, influencing investor sentiment and stock valuation.
Source: Zacks Investment Research
Market Sentiment:
Positive
MetLife Announces 1Q 2026 Results
2 days ago
Quick Summary
MetLife, Inc. (NYSE: MET) reported Q1 2026 net income of $1.1 billion ($1.74/share), up 30%, with adjusted earnings of $1.6 billion ($2.42/share), up 18%, driven by investment income and growth.
Why It Matters
MetLife's strong Q1 results show significant net income and adjusted earnings growth, signaling robust operational performance and potential for future dividend increases, attracting investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
MET anticipates increased net investment income and strong segment growth for Q1, with a consensus EPS estimate up 13.3% year over year.
Why It Matters
Rising net investment income and strong growth forecasts indicate financial strength, while a 13.3% EPS estimate increase suggests improved profitability, signaling potential stock value growth.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Analysts are assessing MetLife's performance for Q1 2026, focusing on key metrics beyond revenue and earnings estimates.
Why It Matters
Evaluating MetLife's key metrics provides insights into its financial health and growth potential, influencing stock performance and investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Positive
MetLife Increases Common Stock Dividend by 4.4%
10 days ago
Quick Summary
MetLife, Inc. announced a Q2 2026 dividend of $0.5925 per share, up 4.4% from Q1. The dividend is payable on June 9, 2026, to shareholders as of May 12, 2026.
Why It Matters
MetLife's dividend increase signals strong financial health and commitment to returning value to shareholders, potentially boosting investor confidence and stock attractiveness.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About MET Stock
What is MetLife Inc.'s (MET) stock forecast for 2026?
Based on our analysis of 26 Wall Street analysts, MetLife Inc. (MET) has a median price target of $89.50. The highest price target is $106.00 and the lowest is $75.00.
Is MET stock a good investment in 2026?
According to current analyst ratings, MET has 12 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $78.08. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MET stock?
Wall Street analysts predict MET stock could reach $89.50 in the next 12 months. This represents a 14.6% increase from the current price of $78.08. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is MetLife Inc.'s business model?
MetLife Inc. generates revenue through a diverse range of insurance products, including life and health insurance, as well as annuities and employee benefit programs. The company serves both individual and institutional clients, offering tailored solutions that address personal and organizational financial needs. Its broad geographic reach allows it to tap into various markets, enhancing its revenue streams.
What is the highest forecasted price for MET MetLife Inc.?
The highest price target for MET is $106.00 from at , which represents a 35.8% increase from the current price of $78.08.
What is the lowest forecasted price for MET MetLife Inc.?
The lowest price target for MET is $75.00 from Elyse Greenspan at Wells Fargo, which represents a -3.9% decrease from the current price of $78.08.
What is the overall MET consensus from analysts for MetLife Inc.?
The overall analyst consensus for MET is bullish. Out of 26 Wall Street analysts, 12 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $89.50.
How accurate are MET stock price projections?
Stock price projections, including those for MetLife Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 9, 2026 10:18 AM UTC